Stay updated on Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Sign up to get notified when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.

Latest updates to the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page
- Check2 days agoChange DetectedThe page shows a revision label updated from v3.3.3 to v3.3.4 in the UI. There are no visible changes to the study history content or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.3.3 was added and the entries for 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page shows a new site revision (v3.3.2), replacing the older revision (v3.2.0), a UI/site version update that does not alter the study history content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedThe government funding lapse notice was removed from the page, eliminating the operating-status alert and leaving the rest of the trial record unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check74 days agoChange DetectedThe new screenshot shows minor UI/layout refinements to the Record History page with no changes to study data, status, or version history content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check102 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference10%

Stay in the know with updates to Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.